Imunon, Inc. (NASDAQ:IMNN) Director Donald P. Braun Acquires 25,000 Shares

Imunon, Inc. (NASDAQ:IMNN) Director Donald P. Braun acquired 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was purchased at an average cost of $1.18 per share, with a total value of $29,500.00. Following the acquisition, the director now directly owns 25,597 shares of the company’s stock, valued at $30,204.46. This trade represents a 4,187.60 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Imunon Stock Down 2.5 %

NASDAQ:IMNN traded down $0.02 during mid-day trading on Tuesday, hitting $0.91. 230,901 shares of the company traded hands, compared to its average volume of 184,877. The stock’s fifty day moving average price is $0.87 and its 200-day moving average price is $1.02. The firm has a market cap of $13.25 million, a price-to-earnings ratio of -0.48 and a beta of 2.04. Imunon, Inc. has a one year low of $0.48 and a one year high of $3.65.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. During the same period in the prior year, the company earned ($0.37) EPS. Equities analysts predict that Imunon, Inc. will post -1.68 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on IMNN shares. D. Boral Capital reissued a “buy” rating and issued a $29.00 target price on shares of Imunon in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Imunon in a report on Thursday, December 19th.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.